ASLAN Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 06, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
Recruitment completed in June for the expansion cohort of the Multiple Ascending Dose (MAD) trial of ASLAN004, underway for the treatment of patients with moderate-to-severe atopic dermatitis Topline,...
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures
July 13, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, July 13, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
Derm-Biome Pharmaceuticals, Inc. files a US provisional patent for a new generation of natural product-based derivatives and their uses for treating chronic inflammatory skin conditions
June 29, 2021 09:30 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is...
Derm-Biome Pharmaceuticals, Inc. adds skin disease and microbiome specialists Drs. Youwen Zhou and Andy Sham to Its Newly Created Scientific Advisory Board
June 02, 2021 08:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, June 02, 2021 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy ageing,...
ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares
March 03, 2021 00:42 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
March 01, 2021 16:01 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis
March 01, 2021 06:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90 - Data supportive of ASLAN004’s potential as a novel,...
ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial
January 11, 2021 05:34 ET
|
ASLAN PHARMACEUTICALS LIMITED
- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels - Data Monitoring...
ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial
October 22, 2020 07:30 ET
|
ASLAN PHARMACEUTICALS LIMITED
-- ASLAN has initiated recruitment of patients into third dose cohort at sites in the US, Australia and Singapore following successful safety review of second cohort -- ASLAN004 found to be...
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis
October 06, 2020 09:30 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is...